[BDSI] BioDelivery Sciences International, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.75 Change: 0.05 (2.94%)
Ext. hours: Change: 0 (0%)

chart BDSI

Refresh chart

Strongest Trends Summary For BDSI

BDSI is in the long-term up 128% above S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioDelivery Sciences International, Inc., a specialty pharmaceutical company, develops and commercializes therapeutics in the areas of pain management and oncology supportive care. The company provides its products based on its patented BioErodible MucoAdhesive (BEMA) drug delivery technology, which consists of a small, bi-layered erodible polymer film for application to the buccal mucosa. Its products include ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in patients with cancer; and BEMA Buprenorphine that is in Phase III trial for the treatment of chronic pain in a mixed opioid naïve and opioid experienced population. The company is also involved in the development of BUNAVAIL for the maintenance treatment of opioid dependence; and Clonidine Topical Gel for the treatment of painful diabetic neuropathy. It has a licensing and development agreement with Endo Pharmaceuticals, Inc. to develop and commercialize BEMA Buprenorphine; and license agreement with Arcion Therapeutics.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.35 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -5.98% Sales Growth - Q/Q412.53% P/E-6.57
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-70.05% ROE-115.89% ROI-109.33%
Current Ratio2.42 Quick Ratio2.34 Long Term Debt/Equity0.05 Debt Ratio0.59
Gross Margin82.95% Operating Margin-150.93% Net Profit Margin-184.52% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.86 M Cash From Investing Activities-140 K Cash From Operating Activities-5 M Gross Profit11.93 M
Net Profit-8.19 M Operating Profit-7.8 M Total Assets82.47 M Total Current Assets71.74 M
Total Current Liabilities29.59 M Total Debt10.26 M Total Liabilities32.62 M Total Revenue13.05 M
Technical Data
High 52 week4.24 Low 52 week1.7 Last close4.24 Last change2.17%
RSI87.12 Average true range0.22 Beta0.68 Volume448.88 K
Simple moving average 20 days17.61% Simple moving average 50 days16.38% Simple moving average 200 days43.4%
Performance Data
Performance Week6% Performance Month19.44% Performance Quart13.98% Performance Half51.43%
Performance Year63.08% Performance Year-to-date14.59% Volatility daily4.48% Volatility weekly10.01%
Volatility monthly20.51% Volatility yearly71.06% Relative Volume117.27% Average Volume642.39 K
New High New Low


2019-03-22 18:24:00 | Lifshitz & Miller LLP Announces Investigation of Alta Mesa Resources, Inc., American Renal Associates LLC, Belden, Inc., BioDelivery Sciences, Inc., Blue Valley Bank Corp., Bridgepoint Education, Inc., and Care.com, Inc.

2019-03-21 17:45:09 | BioDelivery Sciences International BDSI Gains But Lags Market: What You Should Know

2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse

2019-03-18 18:44:10 | Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

2019-03-15 10:23:02 | BioDelivery BDSI Q4 Earnings In Line, Sales Beat, Stock Up

2019-03-14 23:51:23 | Edited Transcript of BDSI earnings conference call or presentation 14-Mar-19 8:30pm GMT

2019-03-14 20:20:00 | Biodelivery Sciences International Inc BDSI Q4 2018 Earnings Conference Call Transcript

2019-03-14 19:45:29 | BioDelivery: 4Q Earnings Snapshot

2019-03-14 16:05:00 | BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations

2019-03-14 14:30:00 | BioDelivery Sciences International, Inc. to Host Earnings Call

2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma

2019-03-12 10:58:13 | BioDelivery Sciences Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

2019-03-12 09:59:01 | Alnylam Files Application for Hypertension Candidate in UK

2019-03-11 14:38:35 | What Kind Of Shareholder Appears On The BioDelivery Sciences International, Inc.’s NASDAQ:BDSI Shareholder Register?

2019-03-11 10:35:02 | AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study

2019-03-11 10:00:02 | What Makes BioDelivery Sciences International BDSI a Strong Momentum Stock: Buy Now?

2019-03-11 09:56:01 | Will the Decade-Old Bull Market Momentum Last? 5 Picks

2019-03-05 16:36:09 | What's in Store for BioSpecifics BSTC This Earnings Season?

2019-03-05 16:06:09 | What's in the Cards for Corbus CRBP This Earnings Season?

2019-03-05 08:44:01 | REGENXBIO RGNX in Focus: Stock Moves 5.1% Higher

2019-03-04 23:40:04 | Champions Oncology CSBR Q3 Earnings: What's in Store?

2019-03-04 23:34:04 | What's in the Cards for Novavax NVAX This Earnings Season?

2019-03-04 08:58:01 | What's in the Cards for Aeterna AEZS This Earnings Season?

2019-03-01 14:20:07 | Endo ENDP Q4 Earnings & Revenues Beat Estimates, Shares Up

2019-03-01 11:59:04 | Amicus FOLD Reports Wider-than-Expected-Loss for 2018

2019-03-01 10:27:03 | The Meet Group MEET to Report Q4 Earnings: What's in Store?

2019-02-28 11:12:04 | Horizon Pharma's HZNP Stock Up on Q4 Earnings & Sales Beat

2019-02-28 08:52:01 | Zacks.com featured expert Kevin Matras highlights: First, Clearfield, BioDelivery Sciences International, MGIC Investment and Kratos Defense & Security Solutions

2019-02-27 07:19:12 | Editas EDIT to Report Q4 Earnings: What's in the Cards?

2019-02-27 07:13:12 | Jazz Pharma JAZZ Q4 Earnings & Sales Beat, Stock Up 8%

2019-02-27 06:24:11 | 5 Affordable Breakout Stocks for Superlative Returns

2019-02-25 07:57:12 | What's in the Cards for Nektar NKTR This Earnings Season?

2019-02-22 16:53:09 | Amgen Starts Phase III Enrollment for Heart Failure Drug

2019-02-22 16:43:09 | What's in Store for Vericel VCEL This Earnings Season?

2019-02-22 16:36:09 | What's in Store for Teladoc's TDOC Q4 Earnings?

2019-02-22 14:46:07 | bluebird BLUE Q4 Earnings Beat Estimates, Revenues Up Y/Y

2019-02-22 09:23:02 | BioMarin BMRN Q4 Earnings & Sales Miss, Shares Decline

2019-02-21 17:45:10 | BioDelivery Sciences International BDSI Dips More Than Broader Markets: What You Should Know

2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

2019-02-21 07:45:00 | BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results

2019-02-20 09:45:02 | Key Factors to Know Ahead of TransEnterix TRXC Q4 Earnings

2019-02-20 09:12:00 | 3 Small Biotechs to Watch as Earnings Season Winds Down

2019-02-20 07:41:12 | Ultragenyx RARE Posts Narrower-Than-Expected Loss in Q4

2019-02-19 10:07:03 | What's in Store for Sangamo SGMO This Earnings Season?

2019-02-19 07:20:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economic Growth

2019-02-18 08:16:01 | What's in the Cards for Amarin AMRN This Earnings Season?

2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock

2019-02-15 10:29:03 | Acorda ACOR Q4 Earnings and Revenues Surpass Estimates

2019-02-15 08:54:01 | Key Factors Likely to Shape CVS Health's CVS Q4 Earnings

2019-02-14 10:45:03 | The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna